Actually, drugs that target podocytes or vasculature, such as SGLT2 inhibitors and DPP-4 inhibitors, as well as drugs that can modulate HIF activity, may lead to next-generation therapeutics that can efficiently mitigate diabetes complications in the kidney. This evidence concerns the gene SLC5A2 and diabetes mellitus.